Scalper1 News
A one-on-one tango has since turned into a full-on hoedown as several major pharmaceutical companies continue to change partners on the M&A floor, with Valeant Pharmaceuticals (VRX) and Pershing Square Capital Management reportedly upping their bid Tuesday for Allergan (AGN) by $15 per share, according to the Wall Street Journal. The new bid would raise Valeant’s bid to about 191 a share. Allergan rose 2% in late trading to 190.20, extending Scalper1 News
Scalper1 News